Selank Research Brief
Anxiety, GABAergic Signaling, and the Evidence Boundary
A synthetic tuftsin analogue with a real but narrow research record—and a much larger online mythology.
Selank is a synthetic heptapeptide derived from tuftsin, an endogenous immunoregulatory peptide fragment.
The evidence does not establish long-term freedom from tolerance, dependence, or withdrawal. It does not establish Selank as a treatment for depression, ADHD, viral illness, or brain injury.
Selank is not FDA-approved. FDA currently discusses Selank acetate in the withdrawn-nomination section of its compounding safety-risk page, citing possible immunogenicity and insufficient human safety information.
What Is Selank?
Selank is a synthetic analogue of tuftsin, a tetrapeptide derived from the heavy chain of human immunoglobulin G. Researchers extended the tuftsin sequence with Pro-Gly-Pro.
Thr-Lys-Pro-Arg-Pro-Gly-Pro
Tuftsin-derived core + Pro-Gly-Pro extension
The literature supports that structural relationship. The six peer-reviewed sources used here do not establish a complete human pharmacokinetic profile, a validated multi-hour plasma half-life, or a quantified rate of delivery into the human brain.
Selank has been used and studied clinically in Russia. Its exact current Russian registration status and approved indication list are not asserted here because those details require confirmation from a current authoritative Russian regulatory source.
Mechanisms Under Investigation
01. GABA-Related Gene Expression
A 2016 rat study found that Selank changed expression of genes involved in neurotransmission and reported overlap with changes observed after GABA administration. This supports possible influence on GABA-related signaling, not a fully mapped human receptor mechanism.
Volkova A, Shadrina M, Kolomin T, et al. Frontiers in Pharmacology. 2016;7:31.02. Enkephalin-Degrading Enzyme Inhibition
An in-vitro study using human serum reported dose-dependent inhibition of enkephalin-degrading enzymes by Selank. This biochemical interaction does not by itself prove anxiolytic, analgesic, or opioid-receptor effects in living humans.
Kost NV, Sokolov OYu, Gabaeva MV, et al. Bioorganicheskaia Khimiia. 2001;27(3):180–183.03. BDNF Expression
A small rodent experiment reported time- and dose-dependent changes in hippocampal BDNF mRNA and protein after intranasal Selank. This does not establish CNS BDNF changes in humans or neuroregeneration.
Inozemtseva LS, Karpenko EA, Dolotov OV, et al. Doklady Biological Sciences. 2008;421:241–243.04. Immune-Signaling Observations
A human study reported changes in Th1/Th2 cytokine balance during treatment, alongside separate in-vitro IL-6 observations. That does not establish immune “boosting,” antiviral protection, or infection prevention.
Uchakina ON, Uchakin PN, Miasoedov NF, et al. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2008;108(5):71–75.The Benzodiazepine Comparison
Selank is often described online as providing benzodiazepine-like anxiety relief without sedation, dependence, tolerance, or withdrawal. The cited human evidence does not support that full claim.
The 2008 comparison involved patients with generalized anxiety disorder or neurasthenia. The abstract reports similar anxiolytic effects, with additional antiasthenic and psychostimulant findings in the Selank group. PubMed indexes the paper as a randomized controlled trial, but the accessible abstract does not provide enough detail to assess allocation, masking, or long-term outcomes.
Selank produced anxiolytic effects similar to medazepam in one small Russian comparison. It does not establish class-wide benzodiazepine equivalence, superiority, or absence of dependence, tolerance, or withdrawal.
Human Research
Anxiety and Neurasthenia
The 62-patient comparison supports further research into anxiolytic activity, but not the breadth of evidence associated with a mature treatment standard.
Cytokine Balance
The companion immune-focused study reported changes in Th1/Th2 cytokine balance during treatment. It is a human biological observation, not proof of broad clinical immune benefit.
Functional Connectivity
A 2020 resting-state fMRI study involving 52 healthy participants reported Selank- and Semax-associated differences in connectivity between the right amygdala and right temporal regions. It did not test clinical anxiety relief or durable cognitive benefit.
Panikratova YaR, Lebedeva IS, Sokolov OYu, et al. Doklady Biological Sciences. 2020;490(1):9–11.Delivery and Pharmacokinetic Limits
Intranasal administration appears in the cited clinical and experimental literature. That route history is not Selank-specific proof of efficient nose-to-brain delivery in humans.
The cited sources do not establish the fraction reaching the human brain, complete circumvention of the blood-brain barrier, a validated human plasma half-life, multi-hour human bioavailability, or sustained clinical effects caused by metabolites.
A studied route of administration is not the same thing as a complete human pharmacokinetic map.
Evidence Boundary
| Claim | Evidence Level | What the Data Shows |
|---|---|---|
| Anxiolytic effects similar to medazepam | HUMAN COMPARATIVE | One 62-patient Russian study; not broad benzodiazepine-class evidence. |
| Cytokine-balance changes | HUMAN OBSERVATION | Limited Th1/Th2 findings; no proof of immune boosting or antiviral benefit. |
| Functional-connectivity changes | HUMAN EXPERIMENTAL | Acute fMRI differences in 52 healthy participants; clinical efficacy was not tested. |
| GABA-related gene expression | PRECLINICAL | Rat frontal-cortex findings; not a complete human receptor mechanism. |
| Enkephalinase inhibition | IN VITRO — HUMAN SERUM | Biochemical inhibition; no direct proof of clinical opioid or anxiolytic effects. |
| BDNF expression changes | PRECLINICAL | Reported in rat hippocampus; not confirmed in the human CNS. |
| Depression, ADHD, or viral treatment | UNESTABLISHED | No credible human efficacy is established by this source set. |
| No tolerance, dependence, or withdrawal | UNESTABLISHED | The small comparison cannot establish long-term absence of these risks. |
Key Limitations
FDA's current page places Selank acetate (TP-7) under “bulk drug substances nominated but withdrawn,” not in the active Category 2 table. FDA cites possible immunogenicity for certain routes and a lack of important human safety information.
Protokol X Assessment
Selank does not need exaggerated claims to be interesting. Evidence supports the narrowest claim first.
Selank is not an invented nootropic story. It has a real, though limited, research record.
The cited literature supports one small human anxiety comparison with medazepam, human-serum in-vitro enzyme inhibition, limited human cytokine observations, acute human fMRI connectivity changes, and preclinical GABA-related and BDNF findings.
It does not establish broad benzodiazepine equivalence, freedom from tolerance or withdrawal, efficacy for depression or ADHD, viral protection, brain repair, or a complete human pharmacokinetic profile.
Selank remains worthy of research because the underlying signals are coherent and biologically interesting. It does not require certainty it has not earned.